2007
The episkin phototoxicity assay (EPA): Development of an in vitro tiered strategy using 17 reference chemicals to predict phototoxic potency
Justine P , Lelièvre D , Christiaens F , Bonaventure N , Coutet J , Marrot L , Cotovio J
MODELS : EPISKIN APPLICATIONS : PHOTOTOXICITY
Toxicol In vitro, 2007 Sep;21(6):977-995
2006
Development of genotoxicity test procedures with Episkin®, a reconstructed human skin model: Towards new tools for in vitro risk assessment of dermally applied compounds?
Nicole Flamanda , Laurent Marrota , Jean-Philippe Belaidia , Linda Bouroufa , Emilie Dourilleb , Michèle Feltesa and Jean-Roch Meuniera
MODELS : EPISKIN APPLICATIONS : GENOTOXICITY
Mutation Research/Genetic Toxicology and Environmental Mutagenesis Volume 606, Issues 1-2, 14 July 2006, Pages 39-51
2004
Iron chelation can modulate UVA-induced lipid peroxidation and ferritin expression in human reconstructed epidermis
Galey J B , Portes P , Seite S , Popovic E , Verdier M P , Fourtanier A , Roguet R , Cohen C
MODELS : EPISKIN APPLICATIONS : PHOTOPROTECTION
Photodermatol Photoimmunol Photomed 2004 Feb ;20 (1):47-52
Gene expression profiles of three different models of reconstructed human epidermis and classical cultures of keratinocytes using cDNA arrays
Mehul B , Bernard D , Bernerd F , Schmidt R , Regnier M , Asselineau D , Leclaire J
MODELS : EPISKIN
Arch Dermatol Res Date: Aug 25 2004 ;
The validation of in vitro methods for skin irritation
Botham P A
MODELS : EPISKIN APPLICATIONS : SKIN IRRITATION OF CHEMICALS
Toxicol Lett 2004 ;149 (1-3):387-90
2002
ECVAM, ECETOC and the EU Chemicals Policy. Alternatives to animal experiments: Progress made and challenges ahead. The proceedings of the ECVAM Status Seminar 2002, held on 4-6 June 2002, in the amphitheatre at the European Commission Joint Research Centr
Botham Philip A
MODELS : EPISKIN APPLICATIONS : SKIN CORROSION , SKIN IRRITATION OF CHEMICALS , OCULAR IRRITATION OF CHEMICAL
ATLA Alternatives to laboratory animals 2002 ;30 (SUP2):185-187
Comparison of cutaneous bioavailability of cosmetic preparations containing caffeine or < alpha >-tocopherol applied on human skin models or human skin ex vivo at finite doses
Dreher F , Fouchard F , Patouillet C , Andrian M , Simonnet J T , Benech Kieffer F
SKIN PHARMACOL APPL SKIN PHYSIOL. Skin Pharmacology and Applied Skin Physiology 2002 ;15 (Suppl. 1):40-58
Improvement of the experimental setup to assess cutaneous bioavailability on human skin models: dynamic protocol
Dreher F , Fouchard F , Patouillet C , Benech Kieffer F , Zanini M , Messager A , Cottin M , Roguet R , Leclaire J
Skin Pharmacol Appl Skin Physiol 2002 ;15 Suppl 1):31-9
Predictive ability of reconstructed human epidermis equivalents for the assessment of skin irritation of cosmetics
Faller C , Bracher M , Dami N , Roguet R
Toxicol In Vitro 2002 ;16 (5):557-72
Reconstructed skin kits: reproducibility of cutaneous irritancy testing
Faller C , Bracher M
Skin Pharmacol Appl Skin Physiol 2002 ;15 Suppl 1):74-91
